Literature DB >> 26741140

Telomere Length as a Prognostic Factor for Overall Survival in Colorectal Cancer Patients.

Houjun Jia1, Ziwei Wang.   

Abstract

BACKGROUND/AIMS: The stabilization of telomere length has important roles in the carcinogenesis of colorectal cancer. A systemic review and meta-analysis of published studies was performed to assess the prognostic role of telomere length in colorectal cancer.
METHODS: Pubmed and Embase were searched for eligible studies on the association between telomere length and overall survival in colorectal cancer patients. The pooled hazard ratio (HR) and corresponding 95% confidence intervals (95%CI) was calculated using fixed-effects or random-effects model according to the magnitude of between-study heterogeneity.
RESULTS: Seven individual studies with a total of 956 colorectal cancer patients were included. Long telomere length in cancer tissues was marginally associated with poorer overall survival (Random-effects HR = 1.85, 95% 0.90 to 3.83, P = 0.09). When using studies with adjusted estimates, long telomere length in cancer tissues was independently and significantly associated with poorer overall survival (Fixed-effects HR = 2.70, 95% 1.51 to 4.84, P = 0.001). However, short telomere length in peripheral blood leukocytes was independently and significantly associated with poorer overall survival (Fixed-effects HR = 2.01, 95% 1.46 to 2.77, P < 0.001).
CONCLUSIONS: There is some evidence for telomere length as a prognostic factor for overall survival in colorectal cancer patients. More studies with large number of participants are needed to further assess the prognostic significance of telomere length in colorectal cancer patients.
© 2016 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2016        PMID: 26741140     DOI: 10.1159/000438614

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  7 in total

1.  Lymphocyte telomere length predicts clinical outcomes of HPV-positive oropharyngeal cancer patients after definitive radiotherapy.

Authors:  Xiaoning Luo; Erich M Sturgis; Zheng Yang; Yan Sun; Peng Wei; Zhensheng Liu; Qingyi Wei; Guojun Li
Journal:  Carcinogenesis       Date:  2019-07-06       Impact factor: 4.944

2.  Obesity and telomere status in the prognosis of patients with colorectal cancer submitted to curative intention surgical treatment.

Authors:  Sergio García-Martínez; Daniel González-Gamo; Tamara Fernández-Marcelo; Sofía Tesolato; Sofía De La Serna; Inmaculada Domínguez-Serrano; Oscar Cano-Valderrama; Ana Barabash; Carmen De Juan; Antonio Torres-García; Pilar Iniesta
Journal:  Mol Clin Oncol       Date:  2021-07-03

3.  Prognostic relevance of telomere length and telomerase reverse transcriptase variant (rs2242652) on the multiple myeloma patients.

Authors:  Salah Aref; Alshaimaa Al Saeed; Nadia El Menshawy; Doaa Abdalla; Mohamed El Ashery
Journal:  J Clin Lab Anal       Date:  2019-12-08       Impact factor: 2.352

4.  Association of TERT gene polymorphisms with clinical benign prostatic hyperplasia in a Chinese Han population of the Northwest region.

Authors:  Guangrui Fan; Kun Li; Yangyang Pang; Youli Zhao; Yan Tao; Huimin Gui; Hanzhang Wang; Robert Svatek; Ronald Rodriguez; Zhiping Wang
Journal:  Transl Androl Urol       Date:  2021-02

5.  Meta-analysis of associations between telomere length and colorectal cancer survival from observational studies.

Authors:  Wei Wang; Lei Zheng; Ning Zhou; Na Li; Gilisihan Bulibu; Chunlei Xu; Yi Zhang; Yong Tang
Journal:  Oncotarget       Date:  2017-08-07

Review 6.  The interplay between immunosenescence and age-related diseases.

Authors:  Florencia Barbé-Tuana; Giselle Funchal; Carine Raquel Richter Schmitz; Rafael Moura Maurmann; Moisés E Bauer
Journal:  Semin Immunopathol       Date:  2020-08-03       Impact factor: 9.623

7.  Telomere in colorectal cancer associated with distant metastases and predicted a poor prognosis.

Authors:  Xiaorong Ye; Jianjiong Li; Chenjun Song; Wenbin Chen
Journal:  Transl Cancer Res       Date:  2021-06       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.